Trial Profile
Prospective, Multicenter, and Nonrandomized Phase II Clinical Study on the Treatment of Locally Advanced NPC By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin
- Indications Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2018 Planned number of patients changed from 186 to 180.
- 21 Jun 2018 New trial record